Sumangha, Samuel .

HRN: 07-68-30  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/12/2026
CEFTRIAXONE 1G (VIAL)
04/12/2026
04/18/2026
IV
2G
OD
HEPATOBILIARY INFECTION
Checking Initial Appropriateness 
04/16/2026
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
04/16/2026
04/22/2026
IV
500 Mg
Q8
Intrabdominal Infection
Checking Initial Appropriateness 
04/25/2026
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
04/25/2026
05/02/2026
IVTT
4.5g
Q6H
Hepatic Abscess
Checking Initial Appropriateness 
04/25/2026
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
04/25/2026
05/02/2026
IVTT
500mg
Q6H
Hepatic Abscess
Checking Initial Appropriateness 
05/04/2026
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
05/04/2026
05/15/2026
IV
500mg
Q6
Hepatic Abscess
Checking Initial Appropriateness 
05/04/2026
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
05/04/2026
05/22/2026
IV
4.5g
Q6
Hepatic Abscess
Checking Initial Appropriateness 
05/15/2026
METRONIDAZOLE 500MG (TAB)
05/15/2026
05/21/2026
ORAL
750mg
Q8
Hepatobilliary Infection
Checking Initial Appropriateness 
05/15/2026
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
05/15/2026
05/21/2026
IV
4.5g
Q6
Hepatobilliary Infection
Checking Initial Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: